期刊
BIOMEDICAL CHROMATOGRAPHY
卷 35, 期 5, 页码 -出版社
WILEY
DOI: 10.1002/bmc.5059
关键词
bioavailability; epidermal growth factor receptor (EGFR) inhibitors; pharmacokinetics; UHPLC-MS/MS
类别
资金
- Province Key R&D Program of Shandong [2019GSF108050]
Targeted inhibition of epidermal growth factor receptor is important in chemotherapy for various malignant tumors. XHL-31, a new candidate, shows significant inhibitory activity against drug-resistant mutations. Gender differences in pharmacokinetics of XHL-31 were observed in rats.
Targeted inhibition of epidermal growth factor receptor has become an important means of chemotherapy for nonsmall cell lung cancer, breast cancer, pancreatic cancer, colon cancer and other malignant tumors. Although remarkable curative effects have been achieved in the past few decades, the emergence of drug resistance is a problem. Therefore, new inhibitors need to be developed. XHL-31 is a new candidate with significant inhibitory activity against T790M and C797S mutations in vitro. In order to study the pharmacokinetics in vivo, a sensitive and efficient UHPLC-MS/MS method was developed for the determination of XHL-31 in rat plasma in this study. The lower limit of quantitation of this method was 1 ng/ml and the linear range was 1-2,000 ng/ml. Method validation showed a high accuracy and precision, a high stability, a high recovery and repeatability. The method was successfully applied to the pharmacokinetic study of XHL-31 in rats. The results indicated that there were significant gender differences in oral absorption and the absolute bioavailability of XHL-31 in female rats were extremely low (<10%).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据